Pharmacokinetic study to the open-label Phase of NUC-5/primary sclerosing cholangitis study
This is an early research study, known as Phase I, which means it's one of the first times this new medicine, NUC-5, is being tested in people. The study is specifically for a liver condition called primary sclerosing cholangitis. The main goal of this particular part of the study is to understand how the body handles the medicine – how it's absorbed, distributed, processed, and removed. This helps researchers work out the best way to give the medicine. At the moment, full details about who can join and what exactly happens in the study aren't available to the public. They will be shared later, within 30 months after the study has finished.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is an early step in developing a new medicine, NUC-5, for a health condition known as primary sclerosing cholangitis (PSC). PSC is a chronic disease that slowly damages the bile ducts in the liver and can eventually lead to serious liver problems. Finding new treatments for conditions like PSC is very important.
Because this is an early study, called a Phase I trial, the main focus is on carefully understanding how NUC-5 behaves in the human body. This includes looking at how much of the medicine gets into the bloodstream, how long it stays there, and how the body breaks it down and gets rid of it. This information is vital for future studies to make sure the medicine is given safely and effectively.
While the detailed information about who can take part and exactly what the study involves isn't public yet, it's reassuring to know these studies are carefully planned and monitored. All the full details will be made available to everyone within 30 months after the study has finished, ensuring transparency once the research has been completed.
النقاط الرئيسية
- This is an early-stage (Phase I) study for a new medicine, NUC-5.
- It's for people with primary sclerosing cholangitis (PSC), a liver condition.
- The main goal is to understand how the body processes the new medicine.
- Full details about the study won't be public until later.
- Only adults aged 18 and over can take part.
من قد يكون مؤهلاً؟
At present, the full information about who can and cannot take part in this study isn't available to the public. This detailed guidance, including specific health requirements and conditions, will be shared later once the study is further along or completed.
What we do know is that participants must be at least 18 years old. Both men and women can potentially join the study. More precise details, such as other health conditions or medicines that might affect participation, will be provided at a later date.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Do you have primary sclerosing cholangitis (PSC)?
- Are you able to commit to potential clinic visits and tests?
- Are you interested in participating in early-stage medical research?
ماذا يتضمن المشاركة؟
Because the full study details are not yet public, we can't tell you exactly what taking part would involve. Generally, in early-stage studies like this, participants might have several visits to a clinic for health checks, to receive the study medicine, and to have blood samples taken. This helps researchers understand how the body reacts to the new medicine.
You would likely be given the new medicine, NUC-5, over a period. There would be follow-up appointments to monitor your health and how you respond to the treatment. The total duration of participation varies greatly in different studies, and we don't have that information yet for this specific trial. All these details will be made clear and explained fully to potential participants once they become available.
المخاطر والفوائد المحتملة
المواقع (2)
- Queen Elizabeth Hospital Birminghamتقريبيبرمنغهام، المملكة المتحدة
- Royal Free Hospitalتقريبيلندن، المملكة المتحدة
أسئلة شائعة
What is primary sclerosing cholangitis (PSC)?
PSC is a long-term liver disease that causes damage to the bile ducts, which carry digestive fluid from your liver. It can lead to serious liver problems over time.
ما هي دراسة 'المرحلة الأولى'؟
Phase I is the earliest stage of human testing for a new medicine. It mainly focuses on safety and how the body handles the medicine, rather than whether it cures a disease.
Why are the full details not available yet?
Sometimes, study details are kept private temporarily to protect the integrity of the research or for commercial reasons. They will be published later.
When will the full study details be available?
The full details will be shared within 30 months after the study has officially finished.
Can children take part in this study?
No, this study is only open to adults aged 18 years and older.
كيفية معرفة المزيد
GKM Gesellschaft fuer Therapieforschung mbH
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.